Journal of Clinical Medicine (Jul 2023)

Apelin-13 as a Potential Biomarker in Critical Illness

  • Marin Gergics,
  • Gréta Pham-Dobor,
  • Csilla Kurdi,
  • Gergely Montskó,
  • Krisztina Mihályi,
  • Gábor Bánfai,
  • Péter Kanizsai,
  • Tamás Kőszegi,
  • Emese Mezősi,
  • László Bajnok

DOI
https://doi.org/10.3390/jcm12144801
Journal volume & issue
Vol. 12, no. 14
p. 4801

Abstract

Read online

Background: The adrenocortical system and copeptin as prognostic markers were intensively investigated in critical illness. The potential predictive power of apelin-13 as a biomarker is largely unknown. We aimed to investigate the prognostic role of apelin-13 in relation to free cortisol, aldosterone, CRH, and copeptin in critically ill patients. Methods: In this prospective observational study, 124 critically ill patients (64 men, 60 women, median age: 70 (59–78) years) were consecutively enrolled at the time of admission. All routinely available clinical and laboratory parameters were evaluated and correlated to hormonal changes. Results: Serum apelin-13 was 1161 (617–2967) pg/mL in non-survivors vs. 2477 (800–3531) pg/mL in survivors (p = 0.054). The concentrations of apelin-13 and CRH had strong positive correlations (r = 0.685, p p p < 0.05). Apelin-13 and free cortisol were independent determinants of survival in the multivariate Cox regression analysis, while copeptin, CRH, or aldosterone were not. Conclusions: Beyond free cortisol, serum apelin-13 may also help refine prognostic predictions in the early phase of critical illness, especially in non-septic patients.

Keywords